CRISPR Therapeutics (NASDAQ:CRSP) Given “Buy” Rating at HC Wainwright

CRISPR Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $65.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 50.12% from the stock’s previous close.

Other analysts also recently issued reports about the company. Bank of America lowered their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Royal Bank of Canada lowered their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research note on Wednesday. TD Cowen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective on the stock in a report on Wednesday. JMP Securities reiterated a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Finally, Chardan Capital reissued a “buy” rating and set a $94.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $75.56.

CRISPR Therapeutics Stock Up 9.3 %

NASDAQ CRSP opened at $43.30 on Thursday. CRISPR Therapeutics has a fifty-two week low of $36.52 and a fifty-two week high of $91.10. The business has a 50 day moving average price of $42.06 and a two-hundred day moving average price of $46.25. The stock has a market cap of $3.70 billion, a PE ratio of -15.30 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. Sell-side analysts anticipate that CRISPR Therapeutics will post -5.08 EPS for the current fiscal year.

Insider Activity

In other news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the transaction, the chief executive officer now owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Several hedge funds have recently added to or reduced their stakes in CRSP. ARK Investment Management LLC increased its holdings in shares of CRISPR Therapeutics by 19.7% during the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after purchasing an additional 1,474,439 shares during the period. State Street Corp increased its stake in CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after buying an additional 599,304 shares during the period. FMR LLC raised its position in shares of CRISPR Therapeutics by 1.0% during the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company’s stock worth $111,632,000 after buying an additional 23,075 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of CRISPR Therapeutics by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company’s stock worth $68,329,000 after acquiring an additional 10,579 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of CRISPR Therapeutics by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after acquiring an additional 35,196 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.